Midnight/Tikun

Dronabinol and Cannabidiol, the active ingredients in Midnight/Tikun, are cannabinoids presented as an inhalation form for inhalation use. They treat nausea and vomiting associated with chemotherapy, stimulate appetite in patients with AIDS or cachexia, and provide analgesic effects for chronic pain.\n\nGNH India supplies Midnight/Tikun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Midnight/Tikun acts on the endocannabinoid system to address several serious conditions.\n\n- Chemotherapy‑induced nausea and vomiting: reduces frequency and severity of episodes.\n- AIDS‑related cachexia: stimulates appetite and supports weight gain.\n- Certain seizure disorders: decreases seizure frequency in eligible patients.\n- Chronic pain: provides analgesic relief where conventional therapies are insufficient.

Adverse reactions may occur with inhaled cannabinoid therapy.\n\nCommon Side Effects:\n- Dizziness\n- Dry mouth\n- Fatigue\n- Nausea\n- Impaired coordination\n- Mood changes\n\nSerious or Rare Side Effects:\n- Psychosis or severe anxiety\n- Marked hypotension\n- Respiratory depression\n- Allergic reactions (rash, angioedema)\n- Worsening of seizure activity\n- Cardiovascular events such as arrhythmia

Use of Midnight/Tikun requires careful clinical consideration.\n\n- Hepatic function: assess before initiating therapy.\n- Psychiatric monitoring: watch for anxiety, depression, or psychotic symptoms.\n- CNS depressants: avoid concurrent use due to additive sedation.\n- Cardiovascular disease: use cautiously in patients with hypotension or arrhythmias.\n- Pregnancy and breastfeeding: safety unknown; avoid unless benefits clearly outweigh risks.\n- Store at ambient temperature: keep in original container, protect from moisture and light.

Midnight/Tikun can interact with several drug classes.\n\nMajor Interactions (Avoid):\n- CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations.\n- Central nervous system depressants (e.g., benzodiazepines): additive sedation risk.\n- Anticoagulants (e.g., warfarin): potential for increased bleeding.\n\nModerate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic effect.\n- Antihypertensives: possible enhancement of hypotensive response.\n- Other cannabinoids: unpredictable pharmacodynamic synergy or antagonism.